Covaxin vaccine for COVID-19 virus reported that soon it would be available for the use of the common public by the end of February 2021. Dr. Sanjay Roy, principal investigator (PI) heading its clinical trial at AIIMS informed as per the IANS report.
Covaxin vaccine is for the Coronavirus, which is developed by Hyderabad-based vaccine manufacturer Bharat Biotech Limited in collaboration with the Indian Council of Medical Research (ICMR).
Dr. Sanjay Roy informed that two domestic vaccine candidates, which are frontrunners, are assumed to hit the market before the end of the first quarter of 2021. The Covishield by Serum Institute of India is also a frontrunner and even in the third phase of clinical trials. And it is expected that it will be soon available for public use around the time of Covaxin.
The Covaxin has entered the third phase of clinical trials at the AIIMS, and more than 100 volunteers have already received the first dose of the vaccine candidate.
He further informed that they have targeted around 26000 volunteers who will be set for the thirds phase of the vaccine’s clinical trial; all the volunteers will get two doses of intramuscular injections at a period of 28 days apart. The trial is double-blinded, and the volunteers will be unplanned assigned to receive COVAXIN or placebo. The lowest age eligibility in the trail is kept at 18 years, and any volunteers who wished to be part of this trial should be adults (above 18 years old)
Article Written by Dikhya Mohanty
Image Source: Google